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Antibiotic susceptibility is sensitive to
metabolites, but how this affects in vivo
treatment efficacy remains unexplored.
Yang, Bhargava et al. characterize
antibiotic-induced changes to the
metabolic environment during infection
and find that direct actions of antibiotics
on host cells induce metabolites that
impair drug efficacy and enhance
phagocytic activity.
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Bactericidal antibiotics alter microbial metabolism
as part of their lethality and can damage mitochon-
dria in mammalian cells. In addition, antibiotic sus-
ceptibility is sensitive to extracellular metabolites,
but it remains unknown whether metabolites pre-
sent at an infection site can affect either treatment
efficacy or immune function. Here, we quantify local
metabolic changes in the host microenvironment
following antibiotic treatment for a peritoneal Es-
cherichia coli infection. Antibiotic treatment elicits
microbiome-independent changes in local metabo-
lites, but not those distal to the infection site, by
acting directly on host cells. The metabolites
induced during treatment, such as AMP, reduce
antibiotic efficacy and enhance phagocytic killing.
Moreover, antibiotic treatment impairs immune
function by inhibiting respiratory activity in immune
cells. Collectively, these results highlight the immu-
nomodulatory potential of antibiotics and reveal
the local metabolic microenvironment to be an
important determinant of infection resolution.
INTRODUCTION
Although the mechanisms of action for most conventional antibi-
otics have beenwell studied (Kohanski et al., 2010), the effects of
antibiotic treatment on human physiology and host-microbe in-
teractions are only beginning to be understood (Willing et al.,
2011). Antibiotics have been observed to alter immune re-
sponses (Anuforom et al., 2015), and there is growing apprecia-
tion that non-specific actions by antibiotics may promote dis-Cell Host & Mease by creating favorable niches for opportunistic pathogens
(Theriot et al., 2014). In light of the pressing challenges of
antibiotic resistance and the diminishing drug discovery pipeline
(Brown and Wright, 2016), there is an urgent need to better un-
derstand the complex consequences of antibiotic treatment dur-
ing infection.
We have previously shown that bacterial metabolism partic-
ipates in the efficacy of bactericidal antibiotics (Belenky et al.,
2015; Dwyer et al., 2014; Lobritz et al., 2015) and that antibiotic
susceptibility is sensitive to extracellular metabolites (Allison
et al., 2011; Meylan et al., 2017). During infection, bacterial
pathogens dynamically remodel their metabolic environment
by inducing host catabolism, disrupting metabolic balance,
and altering the abundance of energy metabolites, amino
acids, and lipids (Beisel, 1975; Dong et al., 2012). However,
it remains unknown how local changes to the metabolic
microenvironment might also alter antibiotic efficacy during
treatment.
Here, we sought to determine whether antibiotic treatment
alters the host metabolic microenvironment and whether such
changes alter antibiotic susceptibility or immune function. We
performed targeted metabolomics on samples from mice
receiving oral antibiotics for a peritoneal infection and found
that antibiotic treatment systemically alters metabolites in the
host, depleting central metabolism intermediates in the perito-
neum. We show that these changes are microbiome indepen-
dent as they also occur in germ-free (GF) mice. Additionally,
we demonstrate that metabolites altered by antibiotic treat-
ment during infection may inhibit antibiotic efficacy and poten-
tiate the phagocytic activity of immune cells. Moreover, we
show that antibiotics directly inhibit respiratory activity in im-
mune cells and can consequently impair their phagocytic
activity. Together, these results indicate that antibiotic-induced
changes to host metabolites and metabolic processes can
significantly affect both treatment efficacy and immune
function.icrobe 22, 757–765, December 13, 2017 ª 2017 Elsevier Inc. 757
RESULTS
Antibiotic Treatment Depletes Central Metabolism
Intermediates in the Peritoneum
To determine whether antibiotics alter metabolites in the host
environment, we quantified metabolites in samples from mice
receiving antibiotic treatment, bacterial infection, or their combi-
nation. We subjected a cohort of 8-week-old C57BL/6J mice to
a set of perturbations including antibiotic treatment with
100 mg/mL ciprofloxacin (cipro) delivered in the drinking water
(ABX), intraperitoneal infection by Escherichia coli ATCC25922
(INF), or their combination (COMB) (Figure 1A). After 24 hr,
mice were euthanized and samples from three tissues were
collected for metabolomic profiling: (1) the peritoneum, to char-
acterize changes in metabolites local to infection; (2) plasma, to
characterize global changes in circulating metabolites; and (3)
the lung, to characterize changes in metabolites distal to infec-
tion. We performed targeted liquid chromatography-tandem
mass spectrometry (LC-MS/MS) on these samples (McCloskey
et al., 2015), enabling absolute quantification for nearly 80 me-
tabolites supporting bacterial growth, including amino acids, nu-
cleotides, and central metabolism intermediates (Table S1).
Hierarchical clustering of these measurements revealed that
the metabolomic profiles clustered first by tissue, then by
perturbation (Figure 1B), indicating that the metabolic changes
elicited by antibiotic treatment or infection were local and tissue
specific. Unsupervised principal component analysis (PCA) re-
vealed that antibiotic treatment systemically altered metabo-
lites in the host environment as samples from ABX mice clus-
tered away from control (CTL) samples in all three tissues
(Figures 1C, S1A, and S1B). In contrast, infection only exerted
local changes, eliciting significant changes in metabolites in
the peritoneum (Figure 1C), but not in the plasma (Figure S1A)
or lung (Figure S1B).
To better understand the antibiotic-induced changes in the
infection microenvironment, we performed multivariate analysis
on the peritoneal samples to identify a metabolite signature
corresponding to antibiotic treatment. We applied elastic net reg-
ularization and partial least-squares discriminant analysis (PLS-
DA) and identified a feature set of metabolites that could discrim-
inate the ABX samples from the union of CTL and INF samples
(Ballabio and Consonni, 2013). This yielded 14 metabolites suffi-
cient for explaining 71% of the variance in metabolites and 40%
of the variance in treatments with 100% calibration accuracy and
100% cross-validation accuracy (Figure 1D). PLS-DA predicted
that antibiotic-associated metabolic changes were most strongly
characterized by depletion in uridine diphosphate (udp), glucose-
6-phosphate (g6p), and ribulose-5-phosphate (ru5p) (Figure 1E).
By inspection, many of these metabolites are intermediates in
the pentose phosphate pathway, glycolysis, and fatty acid
biosynthesis. We performed metabolite set enrichment analysis
(MSEA) on thesemetabolites and found enrichment for ‘‘carbohy-
drate biosynthesis’’ (p = 6.47e4) (Table S2).
Performing a similar analysis on the plasma and lung samples,
we found different metabolite signatures associated with each
tissue (Figures S1C and S1D). While MSEA identified lung me-
tabolites as enriched for ‘‘generation of precursor metabolites
and energy’’ (p = 3.46e3) (Table S3), plasma metabolites
were not specifically enriched for any metabolic pathways with758 Cell Host & Microbe 22, 757–765, December 13, 2017false discovery rate (FDR)-corrected p values below significance
(p = 0.05). We metabolomically profiled additional mice treated
with a higher concentration of cipro (Figure S2A) and found
that 400 mg/mL cipro mostly amplified the antibiotic-induced
changes to host metabolites that we had observed at
100 mg/mL cipro in the peritoneum (Figures S2B and S2C) and
plasma (Figures S2B and S2D), indicated by a further projection
along the first principal component. Together, these data indi-
cate that antibiotic treatment exerts tissue-specific changes in
metabolites in the host environment.
Antibiotic Treatment Elicits Microbiome-Independent
Changes in Host Metabolites
Antibiotics are thought to systemically alter metabolites in the
host environment by acting on the gut microbiome (Reijnders
et al., 2016), but the tissue-specific changes we observed sug-
gested that antibiotics may instead act locally and directly on
host cells. To test this hypothesis, we profiled metabolites from
GF mice treated with 100 mg/mL cipro delivered in the drinking
water (Figure 2A). Surprisingly, we found that many of the tis-
sue-specific changes in metabolites from the conventional
(CONV) mice also occurred in the GF mice lacking a microbiome
(Figure 2B).
To better understand whether the antibiotic-induced
changes to local metabolites in the CONV mice were due to
direct effects on host cells versus effects on the microbiome,
we performed PCA on CTL and ABX samples from both the
CONV and GFmice for each tissue. PCA orthogonally clustered
the peritoneal samples into four distinct quadrants along two
principal components that captured 74% of the variance and
appeared to directly correspond to presence of either a micro-
biome (PC 1) or antibiotic treatment (PC 2) (Figure 2C). More-
over, inspection of metabolites with the greatest PLS-DA load-
ings in the peritoneal ABX signature revealed similar fold
changes in both CONV and GF mice, despite differences in
the untreated CTL concentrations. PCA on the plasma samples
similarly revealed that 83% of the variance in plasma metabo-
lites could be explained by direct effects on host cells instead
of effects on the microbiome (Figure 2D). In contrast, the lung
samples did not separate as cleanly along principal compo-
nents corresponding to a microbiome and antibiotic treatment
(Figure S3). Together, these data indicate that most of the anti-
biotic-induced changes in metabolites are microbiome inde-
pendent and likely due to direct actions of antibiotics on local
host cells.
Antibiotic Treatment Elicits Unique Metabolic Changes
in the Presence of Infection
Because antibiotics are administered to treat infection, we
sought to characterize metabolic changes that occur in the pres-
ence of infection. We first identified an infection-specific meta-
bolic signature by multivariate analysis and then tested whether
the complex changes observed under combination treatment
could be explained by the ABX and INF signatures. We
performed elastic net regularization and used PLS-DA to
discriminate the INF samples from the union of CTL and ABX
samples, identifying a feature set of nine metabolites sufficient
for explaining 90% of the variance in metabolites and 44% of
the variance in treatments with 100% calibration accuracy and
Figure 1. Antibiotic Treatment Depletes
Central Metabolism Intermediates in the
Peritoneum
(A) Experimental design for metabolomic profiling.
C57BL/6J mice were subjected to control condi-
tions (CTL), antibiotic treatment with 100 mg/mL
cipro (ABX), intraperitoneal infection with 107 CFU
(colony-forming units) E. coli (INF), or their combi-
nation (COMB). Peritoneal lavage, plasma, and
lung lavage samples were collected 24 hr after
infection.
(B) Hierarchically clustered heatmap of metabolite
concentrations from CTL, ABX, INF, and COMB
mice.
(C) PCA projection of metabolomic profiles from
peritoneal samples of all four treatment groups.
(D) PLS-DA of peritoneal samples from ABX
mice. Metabolites selected by elastic net regulari-
zation were depleted for central metabolism in-
termediates.
(E) Concentrations for metabolites with large LV1
loadings in peritoneal samples from the ABX
metabolite signature. Antibiotic treatment depleted
uridine diphosphate (udp), glucose-6-phosphate
(g6p), and ribulose-5-phosphate (r5p).
Data are represented as mean ± SEM from n = 3
independent biological replicates. Significance
reported as FDR-corrected p values in comparison
with corresponding CTL conditions: *p % 0.05,
**p% 0.01, ****p% 0.0001.100% cross-validation accuracy (Figure 3A). These were most
strongly characterized by enrichment in guanosine monophos-
phate (gmp) and depletion in adenosine (adn) and AMP (amp)
(Figure 3B). MSEA revealed that these were specifically enriched
for purine metabolic pathways, including terms such as ‘‘purineCell Host & Micnucleotide degradation’’ (p = 1.42e6)
and ‘‘purine nucleotide biosynthesis’’
(p = 1.96e6) (Table S4). Because purine
metabolites can function as important im-
mune signaling molecules (Cekic and
Linden, 2016), these data suggest that
the INF metabolite signature indicated a
local induction of host immunity.
PLS-DA of the peritoneal samples from
all four treatment groups onto the union of
metabolites from the ABX and INF signa-
tures revealed that antibiotic treatment
and infection formed two orthogonal di-
mensions describing the infection micro-
environment with 88% calibration accu-
racy and 83% cross-validation accuracy
(Figure 3C), in close agreement with the
unsupervised PCA of these samples (Fig-
ure 1C). This was supported by the obser-
vation that udp, g6p, and ru5p under com-
bination treatment trended similarly to
antibiotic treatment, and gmp and adn
trended similarly to infection (Figure 3B).
Collectively, these results suggest that
most of the local changes in host metabo-lites associated with antibiotic treatment of infection could be
explained by the independent actions of either antibiotic treat-
ment or infection.
Interestingly, not all of the metabolite changes in the COMB
samples could be explained by the independent actions ofrobe 22, 757–765, December 13, 2017 759
Figure 2. Antibiotic Treatment Elicits Microbiome-Independent Changes in Host Metabolites
(A) Experimental design for germ-free (GF) metabolomic profiling. GF mice were subjected to antibiotic treatment with 100 mg/mL cipro (ABX) and sampled
24 hr later.
(B) Hierarchically clustered heatmaps for changes in metabolite concentrations between ABX and control (CTL) mice, by tissue sample.
(C) Left: PCA projection of metabolomic profiles from CTL and ABX conventional (CONV) and GF mice in the peritoneum. Right: concentrations for peritoneal
metabolites with large peritoneal ABX LV1 loadings in CONV and GF mice.
(D) Left: PCAprojection ofmetabolomic profiles fromCTL and ABX conventional (CONV) andGFmice in the plasma. Right: concentrations for plasmametabolites
with large plasma ABX LV1 loadings in CONV and GF mice.
Data are presented as mean ± SEM from n = 3 independent biological replicates. Significance reported as FDR-corrected p values in comparison with corre-
sponding CTL conditions: **p% 0.01, ***p% 0.001, ****p% 0.0001.antibiotics or infection. For instance, amp was significantly en-
riched in the COMB samples despite being depleted in the INF
samples and unchanged in the ABX samples (Figure 3B). We
subjected additional mice to both infection and antibiotic treat-
ment and sampled the peritoneum at earlier time points. We
found that amp concentrations peaked at 3-fold 6 hr after
infection (Figure S4). COMB samples also scored higher than
the ABX samples on the antibiotic axis (LV 2), suggesting that
infection may potentiate the metabolic changes elicited by anti-
biotic treatment (Figure 3C). To test this, we performed elastic760 Cell Host & Microbe 22, 757–765, December 13, 2017net regularization and used PLS-DA to identify a COMB-specific
metabolite signature discriminating the COMB samples from the
union of CTL, ABX, and INF samples. This comprised 20 metab-
olites sufficient for explaining 55% of the variance in metabolites
and 35% of the variance in treatments with 100% calibration ac-
curacy and 96% cross-validation accuracy (Figure 3D). PLS-DA
predicted that this signature was enriched for thymine (thym) and
amp, and depleted in 3-phospho-D-glyceroyl phosphate
(23dpg) and guanosine (gsn) (Figures 3E and 3B).MSEA revealed
these to be enriched in diverse metabolic processes, including
Figure 3. Antibiotic Treatment Elicits Unique Metabolic Changes in the Presence of Infection
(A) PLS-DA of peritoneal samples from INF mice. Metabolites selected by elastic net regularization were enriched for purine metabolites.
(B) Concentrations for metabolites with large LV1 loadings in peritoneal samples from the INFmetabolite signature. Peritoneal infection increased the abundance
of guanine monophosphate (gmp), and depleted adenosine (adn) and AMP (amp).
(C) PCA projection of peritoneal samples from all four treatment groups using metabolites from the ABX and INF metabolite signatures.
(D) PLS-DA of peritoneal samples from COMB mice. Metabolites selected by elastic net regularization were enriched across diverse pathways.
(E) Concentrations for metabolites with large LV1 loadings in peritoneal samples from the COMBmetabolite signature. The combination treatment increased the
abundance of thymine (thym), and depleted 3-phospho-D-glyceroyl phosphate (23dpg) and guanosine (gsn).
Data are presented as mean ± SEM from n = 3 independent biological replicates. Significance reported as FDR-corrected p values in comparison with corre-
sponding CTL conditions: *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001.various nucleotide, energy, and amino acid metabolism path-
ways (Table S5).
Metabolites Altered by Antibiotic Treatment during
Infection Inhibit Drug Efficacy
Antibiotic efficacy is sensitive to the abundance of extracellular
metabolites (Allison et al., 2011; Meylan et al., 2017). We hypoth-
esized that host metabolites induced by antibiotic treatment of
infection might feed back on drug susceptibility in the pathogen.
To test this hypothesis, we quantified the minimum inhibitory
concentration (MIC) of cipro in E. coli cells following 10 mMsupplementation with thym or amp, which was 13 ng/mL
without supplementation. While thym supplementation did not
appear to alter the MIC (13.5 ng/mL), amp supplementation
significantly decreased cipro susceptibility, increasing the
MIC to 100 ng/mL (Figure 4A). Time-kill experiments with
25 ng/mL cipro revealed that amp supplementation elicited
dose-dependent protection (Figure 4B).
We further characterized changes inMIC promoted by supple-
mentation with metabolites from the COMB, ABX, or INF signa-
tures and found that many of these metabolites also inhibited
drug susceptibility (Figures 4A, 4C, and 4D). MSEA on theseCell Host & Microbe 22, 757–765, December 13, 2017 761
Figure 4. Metabolites Altered by Antibiotic Treatment during Infection Inhibit Drug Efficacy
(A) Cipro MICs following supplementation with 10 mM of each metabolite from the COMB signature.
(B) Dose-dependent reduction in cipro susceptibility by amp. E. coli were treated with 25 ng/mL ciprofloxacin, supplemented with increasing concentrations of
amp (black arrow).
(C) Cipro MICs following supplementation with 10 mM of each metabolite from the ABX signature.
(D) Cipro MICs following supplementation with 10 mM of each metabolite from the INF signature.
Data are presented as mean ± SEM from n R 3 independent biological replicates. Significance reported as FDR-corrected p values in comparison with cor-
responding CTL conditions: *p% 0.05, **p% 0.01, ****p% 0.0001.metabolites identified ‘‘amines and polyamines biosynthesis’’
as the metabolic pathway most enriched by these metabolites
(p = 3.99e4) (Table S6). Together, these results demonstrate
that host metabolites induced by antibiotics during treatment
of infection can feed back and affect antibiotic efficacy.
Direct Actions of Antibiotic Treatment on Immune Cells
Inhibit Phagocytic Killing
Bactericidal antibiotics can impair mitochondrial function in
epithelial cells and inhibit their respiratory activity (Kalghatgi
et al., 2013). In addition, metabolites present in the host microen-
vironment may initiate signaling cascades in immune cells that
lead to metabolic reprogramming and functional changes
(O’Neill and Hardie, 2013). Because efficient phagocytosis in-
volves induction of a highly energy-dependent respiratory burst
(Murphy and Weaver, 2016), we sought to determine whether
antibiotic treatment might also interfere with the respiratory ac-
tivity of immune cells. We pre-treated mouse macrophages
with cipro and measured changes in oxygen consumption
following electron transport chain uncoupling (Figure 5A). These
data revealed a dose-dependent inhibition of respiratory capac-
ity (Figure 5B).
We hypothesized that antibiotic-induced impairments in respi-
ration and/or the induction of local metabolites might physiolog-
ically alter the phagocytic activity of immune cells recruited to a
site of infection. To test this hypothesis, we enumerated E. coli
cells attached or killed by macrophages following treatment762 Cell Host & Microbe 22, 757–765, December 13, 2017with cipro and/or amp. Compared with untreated cells, macro-
phages pre-treated with 20 mg/mL cipro for 3 hr (ABX) engulfed
fewer E. coli cells (Figures 5C and S5A) and possessedmore sur-
viving cells following lysis of the macrophages (Figures 5D and
S5B), indicating a significant decrease in the killing of engulfed
cells (Figure 5E). In contrast, we found that 10 mM amp signifi-
cantly increased pathogen engulfment (Figures 5C and S5C)
and decreased pathogen survival (Figures 5D and S5D),
indicating that metabolites induced at the site of infection by an-
tibiotics may feed forward and potentiate immune function.
Interestingly, antibiotic treatment exerted a dominant-negative
effect over themetabolic potentiation inmacrophages subjected
to both cipro and amp (ABX + amp), most prominently in the abil-
ity to engulf pathogens. Collectively, these results indicate that
antibiotic treatment can directly act on immune cells and meta-
bolically impair their function.
DISCUSSION
Infections are complex host-microbe interfaces composed of
multiple species, cell types, and biochemical species. While
local metabolism is understood to be important for pathogens
to establish their niche, the contribution of antibiotics to this envi-
ronment is poorly understood. Here, we investigated the effects
of antibiotic treatment on host metabolism in a commonly used
and well-defined model of in vivo infection. While antibiotics nor-
mally act in concert with host immune cells to remove pathogens
Figure 5. Direct Actions of Antibiotic Treatment on Immune Cells Inhibit Phagocytic Killing
(A) Changes in macrophage oxygen consumption rate in control (CTL) and cells pre-treated for 3 hr with cipro, following electron transport chain uncoupling by
2 mM oligomycin, 1 mM FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone), and 0.5 mM rotenone + antimycin A.
(B) Changes in respiratory capacity following cipro pre-treatment.
(C) Pathogen engulfment by control (CTL) or macrophages treated with 20 mg/mL cipro (ABX), 10 mM AMP (amp), or their combination (ABX + amp).
(D) Pathogen survival in CTL, ABX, amp, or ABX + amp macrophages.
(E) Phagocytic killing by CTL, ABX, amp, or ABX + amp macrophages.
Data are presented as mean ± SEM from n R 3 independent biological replicates. Significance reported as FDR-corrected p values within the indicated
comparisons: *p% 0.05, **p% 0.01, ****p% 0.0001.at a site of infection, we report that antibiotics also act synergis-
tically with pathogen cells to remodel the local metabolic envi-
ronment (Figure 6). We demonstrate that metabolites induced
in this environment have the capacity to affect both antibiotic
efficacy and immune function and that the direct consequences
of antibiotics on the metabolism of immune cells can inhibit their
phagocytic activity. These data highlight the complex interac-
tions elicited by antibiotics at the site of infection and support
prior in vitro studies demonstrating that the host metabolic envi-
ronment is critical for the function of both antibiotics (Yang et al.,
2017) and immune cells (Buck et al., 2017).
Antibiotics are thought to systemically alter metabolites in the
host by manipulating gut microbiome taxonomy (Reijnders et al.,
2016). We report that orally administered antibiotics also induce
dose-dependent and microbiome-independent changes in me-
tabolites in the host environment. Of significance, we find that
most of themetabolic variation observed in conventionally raised
mice also appeared in GF mice in both the plasma and perito-
neum. These results are consistent with our previous observa-
tions that bactericidal antibiotics directly induce mitochondrial
dysfunction in mammalian cells (Kalghatgi et al., 2013) and
our present observations that antibiotics can inhibit the phago-
cytic activity of immune cells, which require a functioning
respiratory chain for their bactericidal oxidative burst. In our
in vitro experiments, these effects appeared to occur at concen-
trations R1 mg/mL, well within the pharmacokinetic range of
1–5 mg/mL achieved in human serum following oral delivery
and R10 mg/mL in other tissues following intravenous delivery
(Vance-Bryan et al., 1990).
Nutrient availability at a site of infection is an important regu-
lator of antibiotic susceptibility (Amato et al., 2014), and previousstudies have demonstrated that antibiotic tolerance may be
overcome metabolically by stimulating bacterial central meta-
bolism (Allison et al., 2011; Meylan et al., 2017). We report that
diverse metabolites induced by antibiotics at the site of infection
also have the potential to alter both antibiotic efficacy and im-
mune function. An example of this is in the synergistic and local
induction of amp, an energy currency precursor and a participant
in purine metabolism that exerts immunomodulation through
AMP-activated protein kinase (O’Neill and Hardie, 2013). We
find that amp alters E. coli sensitivity to cipro and enhances
phagocytic killing by macrophages. Although the amp concen-
trations that we measured from our bulk lavage of the perito-
neum (10–50 mM) did not exceed theR100 mM required to elicit
an effect on either antibiotic efficacy or immune function, it is
possible that amp concentrations were higher in regional perito-
neal microdomains due to the large surface area and complex
geometry of the peritoneum. Moreover, amp concentrations
are generally 200 mM in mammalian tissues (Traut, 1994) and
can increase >100-fold in human tissues following metabolically
demanding activities such as exercise (Harkness et al., 1983).
Amp therefore may have more significant effects in other tissues
or other in vivo infection models.
While here we use amp to exemplify a single form of complex
metabolic crosstalk between host and microbe physiology in the
context of infection, other metabolites altered at a site of infec-
tion likely also significantly affect antibiotic efficacy or immune
function through undiscovered mechanisms. MSEA identified
polyamine biosynthesis as a metabolic process enriched by
the protective metabolites from ourmetabolite screens. Interest-
ingly, several studies demonstrate that polyamines can protect
pathogens against antibiotic treatment (Kwon and Lu, 2006) byCell Host & Microbe 22, 757–765, December 13, 2017 763
Figure 6. Metabolic Effects of Antibiotic Treatment on Host Cells
Inhibit Drug Efficacy and Impair Immune Function
During infection, antibiotics work in concert with immune cells to clear mi-
crobial pathogens (black lines). Meanwhile, antibiotics and pathogen cells
metabolically remodel the local infectious microenvironment by acting on local
host cells (dashed lines). Induced metabolites can inhibit drug efficacy and
potentiate immune function (purple lines). Direct actions by antibiotics on im-
mune cellmetabolism can also impair immune cell phagocytic activity (red line).inhibiting drug uptake (Sarathy et al., 2013), inducing protective
stress responses (Tkachenko et al., 2006), and reducing anti-
biotic-induced reactive oxygen species (Tkachenko et al.,
2012). Future studies will need to clarify the mechanisms by
which diverse metabolites may alter antibiotic efficacy (Yang
et al., 2017).
Finally, our work identifies the local metabolic microenviron-
ment as an important determinant in the resolution of infection,
due to its actions on antibiotic susceptibility and immune func-
tion. It is likely that interpersonal differences in the combination
of such metabolites may contribute to variable treatment out-
comes across patients suffering from similar infections (Lee
and Collins, 2011). Additionally, dynamic changes to these envi-
ronments, for instance by prophylactics, may be useful for maxi-
mizing both antibiotic efficacy and immune function. As recogni-
tion of metabolic context dependence for antibiotic efficacy is
growing for important human pathogens (Black et al., 2014),
our findings support the use of metabolic adjuvants to enhance
our existing antibiotic arsenal (Wright, 2016).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial Strains, Media, Growth Conditions
Escherichia coli strain ATCC25922 was purchased from the American Type Culture Collection (ATCC) and used for all experiments in
this study. Cells were cultured in tryptic soy broth (TSB) and grown at 37C on a rotating shaker at 300 rpm in flasks or 14 mL test
tubes or at 900 rpm in 96-well plates.
Vertebrate Animals
Conventional and germ-free 8-week old male C57BL/6J mice were acquired from Jackson Labs (Bar Harbor, ME) and used for all
experiments in this study. Once received, conventional mice were housed at the Harvard Institute of Medicine Vivarium and
germ-free mice housed at the Gnotobiotic and Microbiology Core Facility at Brigham and Women’s Hospital. All mice were socially
housed and monitored daily for 7 days before experiments to permit acclimatization. Following intra-peritoneal infection and/or
antibiotic treatment, mice were monitored twice for signs of dehydration and water intake and observed for signs of potential pain
or distress associated with any intestinal discomfort. Animal protocols for the experiments performed in this study were approved
by the Harvard Medical School Institutional Animal Care and Use Committee and all experiments conform to relevant regulatory
standards.
Cell Lines
Immortalized mouse SV129 macrophages were derived from a bone marrow cell line from male SV129 mice and authenticated by
qPCR (Lee et al., 2006). Macrophages were maintained in 1 g/L glucose DMEM (Cell-Gro; Manassas, VA) supplemented with 10%
FBS and 1% penicillin/streptomycin. SV129 macrophages were loaded onto 24-well tissue culture treated plates at 5,105 macro-
phages/well the day before experiment.e1 Cell Host & Microbe 22, 757–765.e1–e3, December 13, 2017
METHOD DETAILS
Materials and Reagents
Ciprofloxacin (cipro) and all metabolites used as metabolic perturbations or metabolomic profiling standards were purchased from
Sigma-Aldrich (St. Louis, MO). BD Difco TSB and tryptic soy agar were purchased from Fisher Scientific (Hampton, NH). Uniformly
labeled 13C glucose was purchased from Cambridge Isotope Laboratories (Tewksbury, MA). LC-MS reagents were purchased from
Honeywell Burdick & Jackson (Muskegon, MI) and Sigma-Aldrich.
Animal Experiments
8-week old male C57BL/6J mice were intraperitoneally injected with 107 CFU E. coli cells in sterile saline. Control water or drinking
water containing 100 or 400 mg/mL cipro was introduced 4 h post infection. These concentrations were selected based on an esti-
mate that a typical 25 g mouse drinks 4 mL of water each day, yielding a daily dose of 16 or 64 mg/kg/day cipro, which is in the
10-250 mg/kg/day range typically used to treat humans. Mice were sacrificed 20 h later; blood was harvested by cardiac puncture
and plasma was isolated using lithium heparin tubes (Greiner Bio-One; Kremsm€unster, Austria), according to the manufacturer’s in-
structions. The peritoneum was lavaged with 5 mL sterile PBS in 2.5 mL increments. The lung was lavaged through the trachea with
5 mL sterile PBS in 0.7 mL increments. All samples were kept on ice following collection.
Metabolomic Profiling
Metabolites were acquired and quantified on an AB SCIEX Qtrap 5500 mass spectrometer (AB SCIEX; Framingham, MA) and pro-
cessed using MultiQuant 3.0.1, as described previously (McCloskey et al., 2015). Metabolite extractions were performed using a
40:40:20 mixture of acetonitrile, methanol and LC-MS grade water in Phree Phospholipid Removal tubes (Phenomenex; Torrance,
CA). Uniformly labeled 13C-standards were generated by growing E. coli in uniformly labeled GlucoseM9minimal media in aerated
shake flasks, as previously described (McCloskey et al., 2014). Calibration mixes of standards were split across several mixes,
aliquoted, and lyophilized to dryness. All samples and calibrators were equally spiked with the same internal standards. Samples
were quantified using isotope-dependent mass spectrometry. Calibration curves were run before and after all biological and
analytical replicates. Consistency of quantification between calibration curves was checked by running a Quality Control sample
composed of all biological replicates. Values reported are derived from the average of the biological triplicates, analyzed in dupli-
cate (n = 6).
Minimum Inhibitory Concentrations
Minimum Inhibitory Concentrations (MICs) were determined bymicrobroth dilution in 96-well microtiter plates with 1.5-fold step sizes
of cipro dissolved in TSB, as previously described (Andrews, 2001). Approximately 104 CFU E. coli suspended in TSB supplemented
with 2-20mMof eachmetabolite were added to eachwell of the 96-well plates to achieve a total volume of 200 mL. Plates were sealed
with a breathable membrane and then incubated at 37C with 900 rpm shaking for 20 h. Following incubation, OD600 was quantified
on a SpectraMax M3 plate reader. MIC experiments were performed in at least triplicate from independent overnight cultures with
values reported as the mean ± SEM.
Time-Kill Experiments
Time-kill experiments were performed as previously described (Dwyer et al., 2014). Briefly, an overnight culture of E. coli cells in TSB
was diluted 1:1,000 and grown toOD6000.1 at 37Cwith 300 rpm shaking prior to experiment. 1mL cultures were then dispensed to
14mL test tubes and treatedwith cipro and/or amp. Hourly sampleswere collected and serially diluted in PBS for colony enumeration
24 h later.
Macrophage Assays
In vitro phagocytosis assays were adapted from previously published protocols (Sokolovska et al., 2012) and performed using SV129
macrophages. On the day of experiment, culture media was replaced with 1 g/L DMEM supplemented with 1% FBS. E. coli cells
grown to OD600 0.3 in TSB and antibiotics were added to macrophages on ice for 30 min to synchronize phagocytosis. Plates
were then incubated at 37C for 30 min with a control plate maintained on ice to quantify E. coli cells engulfed, but not killed. Cells
were washed thrice with PBS + 0.5mMEDTA. Cells were lysed with pH 11.5 H2O for 4min and serially diluted for colony enumeration
24 h later.
Oxygen Consumption Rate Quantification
Macrophage respiratory activity was quantified using the Seahorse XF Cell Mito Stress Test Kit and XFe96 Extracellular Flux Analyzer
(Seahorse Bioscience; North Billerica, MA), according to themanufacturer’s instructions. Briefly, SV129macrophages were plated at
a density of 125,000 cells per well and cultured overnight before the start of the experiment. Cells were PBS washed and then pre-
treated with cipro for 3 h in the XF Base Medium (Seahorse Bioscience; North Billerica, MA). The Mito Stress Test Kit assay was then
performed using 2 mM oligomycin, 1 mM FCCP and 0.5 mM rotenone/antimycin A. Respiratory capacity was computed as the differ-
ence in oxygen consumption rate following FCCP treatment and following rotenone/antimycin A.Cell Host & Microbe 22, 757–765.e1–e3, December 13, 2017 e2
QUANTIFICATION AND STATISTICAL ANALYSIS
Experimental Replicates
All in vivometabolomic quantification experiments were performed using n = 3 mice in each treatment condition, with samples pre-
pared in technical duplicate, yielding n = 6 samples for each condition. In vitro MIC estimations following metabolite supplementa-
tions were performed using n = 3-6 biological replicates of E. coli cells on different days. Time-kill experiments involving E. coli cells
were performed in biological triplicate on different days. Oxygen consumption experiments were performed in biological triplicate
with n = 5 technical replicates in different wells of the 96-well Seahorse cartridges on different days. In vitromeasurements of immune
function using SV129 mouse macrophages were performed with n = 3-4 biological replicates on different days, with n = 4 technical
replicates on 24-well tissue-culture treated plates.
Metabolite Quantification
Metabolite concentrations were estimated from LC-MS/MS peak heights using previously generated calibration curves. Metabolites
found to have a quantifiable variability (RSD R 50%) in the Quality Control samples or possessing individual components with a
RSDR 80%were excluded from analysis. Metabolites in blanks with a concentration greater than 80%of that found in the biological
samples were similarly excluded. Missing values were imputed by bootstrapping using the R package Amelia II (v. 1.7.4, 1,000 im-
putations) (Honaker et al., 2011). Remaining missing values were approximated as ½ the lower limit of quantification for
the metabolite normalized to the biomass of the sample. Metabolite concentrations from the peritoneum and lung were scaled
300- and 125-fold, respectively, to account for the dilution effect by a 5 mL lavage based on estimated peritoneal fluid volume
of 16 mL (Hartveit and Thunold, 1966) and estimated lung alveolar fluid volume of 40 mL (Korfhagen et al., 1996).
Multivariate Analysis
Metabolite concentrations were first pre-processed with the generalized log transformation using the R package LMGene (v. 3.3) (Lu
et al., 2008) and then centered to achieve an approximately normal distribution. Hierarchical clustering, principal components anal-
ysis and elastic net regularization were performed in MATLAB 2016b (MathWorks; Natick, MA). Partial least squares discriminant
analysis was performed using the MATLAB package Classification Toolbox (v. 4.0) (Ballabio and Consonni, 2013).
Metabolite Set Enrichment Analysis
Metabolite Set Enrichment Analysis (MSEA) was performed in Ecocyc (v. 20.1) (Keseler et al., 2017). SmartTables were created
comprised of metabolites from each metabolite signature and pathways were identified using the ‘‘Enrichment and Depletion’’ anal-
ysis type. The Fisher Exact test was performed for each enrichment analysis with FDR correction by the Benjamini-Hochberg
method.
Statistical Analysis
Statistical significance testing was performed in Prism v7.0b (Graphpad; San Diego, CA). One-way ANOVA was performed on data
from all experiments. Reported p-values reflect false-discovery correction by the Holm-Sı´da´k multiple comparisons test, with com-
parisons against either only the relevant control condition, or only against specific other conditions as indicated. Although ANOVA is
generally robust against lack of normality in the data, statistical tests were not specifically performed to determine if all of the assump-
tions of ANOVA had been met.e3 Cell Host & Microbe 22, 757–765.e1–e3, December 13, 2017
